Prohibition Partners
Home / Cannabis Markets / Norway
Norway flag

Is cannabis legal in Norway?

Medical cannabis is legal in Norway and adult-use is illegal. Below: a free market overview, with the full sizing, regulation and trade data available from PP.

Medical: LegalAdult-use: Illegal

Market size

Medical cannabis sales and registered patients in Norway, 2025 actuals and the 2027 forecast. Forecasts to 2030 are in the Norway data pack.

Medical sales, EUR

€650.1k2025€712.9k2026€775.7k2027202820292030
Metric202520262027202820292030
Medical sales€650.1k€712.9k€775.7k
Patients444487529

Forecasts to 2030 — sales, patients and the full Norway series — are in the Norway data pack, or scoped to your question in a bespoke brief.

See the data pack Request a brief

Source: Prohibition Partners — Global Medical Cannabis Market Review (2026, updated April 2026) & The European Cannabis Report (2025)

Recently in Norway

From International Cannabis Weekly, our free global briefing.

Latest issue №467
  1. Italy appeals to European Commission to save hemp industry; Norway launches legalisation initiative

    362 · 16 Aug 2024 · Hemp & CBD

  2. Norway hosts first public meeting on medical cannabis towards potential reform

    BusinessCann · 285 · 10 Feb 2023 · Medical

  3. Government of Norway moves to decriminalise possession of cannabis

    Marijuana Moment · 186 · 26 Feb 2021 · Regulation

  4. Norway's sovereign wealth fund blacklists cannabis stocks after criticism

    ipe.com · 98 · 31 May 2019 · Business & Investment

  5. Norway decriminalises cannabis to roll back repressive drug policies

    The Independent · 36 · 16 Mar 2018 · Regulation

  6. Norway to differentiate from repressive Scandinavian cannabis policies

    36 · 16 Mar 2018 · Regulation

Medical cannabis — overview

In November 2016, Norway issued new guidelines regarding medical cannabis and approval exemptions. In Norway, unregistered medical cannabis products (flowers and oils) containing more than 1% THC may be prescribed through an application for an approval exemption, which is approved by the Norwegian Medicines Agency (DMP).

There is no official list of approved conditions in which the use of these medicines is relevant; however, patients who receive approval usually have severe pain and have exhausted all other forms of treatment.

To prescribe unregistered cannabis products over 1% THC, specialists must provide a justification why other forms of approved medicines are not suitable for the patient. Once the DMP approves the exemption, the hospital pharmacy delivers the product to the patient, for which the pharmacy wholesaler must obtain an import permit from the DMP.

Unregistered cannabis medicines that have been made available to patients include flowers by Bedrocan, magistral oils made from the Danish Glostrup pharmacy and oil drops from Stenocare. If a public hospital offers cannabis treatment, the health authorities cover the cost of the treatment; however, if specialists outside of a public hospital offer treatment, the patient must pay out of pocket.